Trevena Stock News

-- 92% probability that TRV027 has a potential beneficial impact on primary endpoint of D-dimer levels, a biomarker associated with critical illness and mortality

CHESTERBROOK, Pa., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with ce

CHESTERBROOK, Penn., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Trevena, Inc. (Nasdaq: TRVN), a biopharmaceutical company focused on the development and commercialization of novel medicines for patients with c

-- Study is being led by Cleveland Clinic; designed to evaluate potential benefit of OLINVYK on respiratory, GI, and cognitive function outcomes in postoperative patients

ADXN, CSSE, HSDT, LYRA, and TRVN have been added to the Zacks Rank #5 (Strong Sell) List on August 20, 2021.

Trevena recently reported disappointing Q2 earnings that revealed they completely missed the Street's expectations and only pulled in ~$180K in revenue. The COVID-19 headwinds are slamming Trevena and

Trevena's (TRVN) CEO Carrie Bourdow on Q2 2021 Results - Earnings Call Transcript

Shares of Trevena (NASDAQ:TRVN) rose 0.7% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share decreased 50.00% over the past year to ($0.09), which missed

Company reaffirms YE goal of 100 formulary wins

Exploratory analysis shows OLINVYK treated patients are ~50% less likely to experience an AE compared to morphine patients at equivalent levels of analgesia Exploratory analysis shows OLINVYK treated

TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medical Center (VUMC) TRV027 will be dosed in ~300 patients in nationwide trial led by Vanderbilt University Medi

Glass Lewis and Institutional Shareholder Services (ISS) independently recommend that Trevena shareholders vote “FOR” proposals to approve a Reverse Stock Split and concurrent Authorized Share Red

Models demonstrate substantial overall cost savings for hospitals when using OLINVYK compared to IV morphine in postoperative care

Nhwa is conducting and funding this study to support NDA regulatory filing in China

Trevena Inc (NASDAQ: TRVN) has announced that the National Institute on Drug Abuse (NIDA), part of the NIH, has resumed recruitment for its proof-of-concept study for TRV734. The Company has collab